Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

June 6, 2024

Study Completion Date

June 6, 2024

Conditions

Moderate to Severe Asthma

Interventions

DEVICE

3% Hypertonic Saline

4 mL of 3% hypertonic saline

DEVICE

7% Hypertonic Saline

4 mL of 7% hypertonic saline

DRUG

Salbutamol

4 puffs (90 mcg/actuation)

Trial Locations (1)

Center for Environmental Medicine, Asthma and Lung Biology, Chapel Hill

All Listed Sponsors

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT03556683 - Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics | Biotech Hunter | Biotech Hunter